ZNF224 and chronic myelogenous leukemia, BCR-ABL1 positive: In agreement with these findings, we demonstrated that treatment of CML cells with Bcr-Abl inhibitors, such as Imatinib and second generation TKIs increases ZNF224 expression [25].